Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson Progress
0% Complete
Foundational Principles and Pathophysiology of Death Rattle

Foundational Principles and Pathophysiology of Death Rattle

Objectives Icon A target symbol, representing a learning objective.

Lesson Objective

Describe foundational principles of death rattle (management of secretions) including its epidemiology, pathophysiology, risk modifiers, and social determinants.

1. Epidemiology and Incidence

Death rattle—the noisy, gurgling sound from pooled oropharyngeal and bronchial secretions—affects roughly one-third to one-half of patients in the final hours to days of life. Incidence varies by setting, primary diagnosis, and measurement methods.

  • Prevalence Range: 12%–92%, with a weighted mean of approximately 35%–50%.
  • Setting Differences: Incidence is highest in hospice settings (~60%), followed by acute care wards (~40%) and intensive care units (~30%).
  • Higher Rates Associated With: Advanced thoracic or abdominal malignancies and prolonged sedation.
  • Patient and Family Impact: While patients are often unaware of the sound, up to 80% of families find it distressing.
Pearl Icon A lightbulb, symbolizing a clinical pearl or key insight. Clinical Pearl: A Window for Communication

The onset of death rattle often precedes death by 12–48 hours. This timeframe presents a critical opportunity for timely goals-of-care discussions and to prepare the family for the final stages of the dying process.

2. Pathophysiology of Secretion Accumulation

Normal airway clearance relies on an effective cough, swallowing reflexes, mucociliary transport, and a sufficient level of consciousness. In terminal illness, central nervous system depression and the loss of protective reflexes lead to pooled secretions that generate audible gurgling during respiration.

Pathophysiology of Death Rattle A flowchart showing two primary pathways leading to death rattle. Type 1 involves impaired swallowing leading to pooled salivary secretions. Type 2 involves impaired cough reflex leading to pooled bronchial secretions. Both pathways result in turbulent airflow and the characteristic gurgling sound. Type 1: Salivary Secretions Impaired swallowing reflex Type 2: Bronchial Secretions Impaired cough reflex or infection Turbulent Airflow “Rattle” on inspiration/expiration
Figure 1: Dual Pathophysiology of Death Rattle. The sound originates from turbulent airflow through either pooled oropharyngeal (Type 1) or bronchial (Type 2) secretions, which accumulate due to failing protective airway reflexes.

The fluid balance of the patient can also influence the character of secretions. Dehydration may lead to thickened, tenacious secretions, while overhydration can increase the volume of pooled fluid.

Pearl Icon A lightbulb, symbolizing a clinical pearl or key insight. Clinical Pearl: Phenotype-Guided Treatment

Identifying the likely source of secretions can guide therapy. Type 1 (salivary) death rattle often responds best to anticholinergic medications that reduce saliva production. Type 2 (bronchial) may require therapies aimed at the lower airways, such as antibiotics for an underlying pneumonia or bronchodilators, although the utility of these is limited in the imminently dying patient.

3. Chronic Disease as a Risk Modifier

Pre-existing neurological, pulmonary, and head/neck comorbidities significantly increase a patient’s susceptibility to secretion pooling by either impairing protective reflexes or increasing the baseline secretion burden.

Risk Modifiers for Death Rattle
Comorbidity Category Underlying Mechanism Clinical Examples
Neurological Depression of cough and swallow reflexes Advanced dementia, stroke, brain tumors, high-dose opioids/sedatives
Pulmonary Increased bronchial secretion production COPD, pneumonia, lung metastases, heart failure
Structural Anatomic obstruction and dysphagia Head and neck tumors, post-radiation changes
Pearl Icon A lightbulb, symbolizing a clinical pearl or key insight. Clinical Pearl: Balancing Sedation and Airway Protection

Incorporate neurological status and sedation level into risk stratification. When possible, titrate sedative and opioid dosing to achieve comfort while preserving minimal protective reflexes, such as glottic function, to delay the onset of secretion pooling.

4. Social Determinants of Health

The management of death rattle and the resulting family experience are profoundly shaped by social and environmental factors, including access to care, caregiver literacy, and cultural beliefs.

  • Resource Access: The availability of anticholinergic medications, portable suction devices, and humidifiers can differ greatly between home, hospice, and hospital settings.
  • Health Literacy: A caregiver’s ability to understand that death rattle is a natural part of the dying process, rather than a sign of suffering, is crucial for reducing their anxiety and preventing requests for potentially burdensome interventions.
  • Care Setting: Home and hospice care typically emphasize non-invasive, comfort-focused measures like repositioning. In contrast, an ICU setting allows for more aggressive interventions like deep suctioning, which may not improve patient comfort and can be distressing to observe.
  • Cultural Beliefs: Family and cultural perspectives on the dying process influence goals of care and the acceptance of non-interventionist approaches.
Pearl Icon A lightbulb, symbolizing a clinical pearl or key insight. Clinical Pearl: Use Teach-Back to Alleviate Anxiety

To confirm caregiver understanding and reduce anxiety, use simple teach-back techniques. After explaining the phenomenon, ask, “To make sure I’ve explained it well, can you tell me in your own words what you understand about this sound?” This empowers the caregiver and clarifies misconceptions.

5. Clinical Presentation and Goals of Care

Death rattle typically appears as low-pitched, bubbling respirations in a minimally responsive patient who shows no signs of active distress. Distinguishing this sound from true dyspnea is essential to avoid unnecessary and potentially harmful interventions.

  • Audible Signs: Gurgling or rattling sounds are heard at the bedside, often on both inspiration and expiration.
  • Absence of Distress: Crucially, there is minimal change in respiratory rate, no tachypnea, no use of accessory muscles, and no patient agitation.
  • Goals of Care: The primary goal is to support the family and honor patient preferences. This involves clarifying wishes regarding suctioning, medication use, and non-pharmacologic measures like repositioning the head.
  • Communication: A core intervention is explaining to observers that death rattle is not believed to be painful or distressing for the patient, even though it may be upsetting to hear.

Case Vignette

A 78-year-old man with end-stage lung cancer becomes unresponsive and develops gurgling respirations. His vital signs are stable, and his breathing is unlabored. The care team explains to his daughter that this is a natural sound associated with the dying process. They offer to reposition his head to quiet the sound and discuss the option of prophylactic subcutaneous glycopyrrolate to reduce secretions. After the education and repositioning, the daughter’s anxiety visibly decreases.

Key Takeaways Icon A key symbol, representing key takeaways.

Key Management Principles

  • Death rattle is not respiratory distress. Always assess the patient’s work of breathing separately to rule out dyspnea.
  • Prophylactic anticholinergics (e.g., scopolamine butylbromide, glycopyrrolate) may reduce the incidence of death rattle when initiated early in high-risk patients.
  • Oropharyngeal suctioning often causes discomfort without providing lasting benefit and should generally be avoided.
  • Family education, compassionate communication, and presence at the bedside are the mainstays of care.

References

  1. Lokker ME, van Zuylen L, van der Rijt CCD, van der Heide A. Prevalence, impact, and treatment of death rattle: a systematic review. J Pain Symptom Manage. 2014;47(1):105–122.
  2. Heisler M, Hamilton G, Abbott A, et al. Randomized double-blind trial of sublingual atropine vs placebo for death rattle. J Pain Symptom Manage. 2013;45(1):14–22.
  3. van Esch HJ, van Zuylen L, Geijteman ECT, et al. Effect of prophylactic scopolamine butylbromide on death rattle: the SILENCE trial. JAMA. 2021;326(12):1268–1276.
  4. Campbell ML, Yarandi HN. Death rattle is not associated with patient respiratory distress: is pharmacologic treatment indicated? J Palliat Med. 2013;16(10):1255–1259.
  5. van Esch HJ, Lokker ME, Rietjens J, et al. Understanding relatives’ experience of death rattle. BMC Psychol. 2020;8:62.
  6. Moons L, De Roo ML, Deschodt M, Oldenburger E. Death rattle: experiences and non-pharmacological management—a narrative review. Ann Palliat Med. 2024;13(1):150–161.
  7. Shimizu Y, Miyashita M, Morita T, et al. Care strategy for death rattle: insights from a nationwide survey of bereaved families. J Pain Symptom Manage. 2014;48(1):2–12.
  8. Yamaguchi T, Yokomichi N, Yamaguchi T, et al. Anticholinergic drugs for death rattle in dying cancer patients: prospective cohort study. BMJ Support Palliat Care. 2023;13(4):462–471.
  9. Dayan D, Menahem S, Shvartzman P. End-of-life hydration and death rattle occurrence. Support Care Cancer. 2021;29(1):179–185.
  10. Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;(1):CD005177.